Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease: Experimental Physiology - Symposium Report

Experimental Physiology

Volumn 94, Issue 2, 2009, Pages 171-174

  Mall, Marcus A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; EPITHELIAL SODIUM CHANNEL; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CONFERENCE PAPER; CYSTIC FIBROSIS; EPITHELIUM; GENE MUTATION; HUMAN; LUNG FIBROSIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; SODIUM ABSORPTION;

EID: 58449116969     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.042994     Document Type: Conference Paper

References (22)

1. Adkins B, Leclerc C & Marshall-Clarke S (2004). Neonatal adaptive immunity comes of age. Nat Rev Immunol 4, 553 564.
2. Chen CJ, Kono H, Golenbock D, Reed G, Akira S & Rock KL (2007). Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13, 851 856.
3. Churg A & Wright JL (2005). Proteases and emphysema. Curr Opin Pulm Med 11, 153 159.
4. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL & Wohl ME (1994). Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331, 637 642.
5. Hirsh AJ, Zang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater J, Abraham WM, Donowitz M, Cha B, Johnson KB, St George J, Johnson MR & Boucher RC (2008). Pharmacological properties of 552-02, a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325, 77 88.
6. Knowles MR, Gatzy JT & Boucher RC (1981). Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305, 1489 1495.
7. + absorption in airway epithelial cells with mucosal nystatin treatment. Am J Respir Cell Mol Biol 38, 423 434.
8. + conductance is reduced by CFTR in normal but not in cystic fibrosis airways. J Clin Invest 102, 15 21.
9. Mall M & Boucher RC (2006). Pathogenesis of pulmonary disease in cystic fibrosis. In Cystic Fibrosis in the 21st Century, ed. Bush A, Alton E, Davies J, Griesenbach U & Jaffe A, pp. 116 121. Karger, Basel.
10. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10, 487 493.
11. + conductance when coexpressed in Xenopus oocytes. FEBS Lett 381, 47 52.
12. Mall MA (2008). Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 21, 13 24.
13. + channel-overexpressing mice. Am J Respir Crit Care Med 177, 730 742.
14. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW & Boucher RC (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005 1015.
15. Pons G, Marchand MC, d'Athis P, Sauvage E, Foucard C, Chaumet-Riffaud P, Sautegeau A, Navarro J & Lenoir G (2000). French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 30, 25 31.
16. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev K, Borowitz D, Bowman CM, Marshall BC, Marshall S & Smith AL (1999). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340, 23 30.
17. Rolfe MW, Kunkel SL, Rowens B, Standiford TJ, Cragoe EJ Jr. & Strieter RM (1992). Suppression of human alveolar macrophage-derived cytokines by amiloride. Am J Respir Cell Mol Biol 6, 576 582.
18. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC & Boucher RC (1995). CFTR as a cAMP-dependent regulator of sodium channels. Science 269, 847 850.
19. Syntichaki P & Tavernarakis N (2002). Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? EMBO Rep 3, 604 609.
20. Walter MJ, Morton JD, Kajiwara N, Agapov E & Holtzman MJ (2002). Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest 110, 165 175.
21. Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC & Mall MA (2008). Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 178, 1245 1256.
22. Zuelzer WW & Newton WA (1949). The pathogenesis of fibrocystic disease of the pancreas; a study of 36 cases with special reference to the pulmonary lesions. Pediatrics 4, 53 69.